Biomaterial Database

Thyroxine as a stimulator of liver regeneration after partial hepatectomy: an experimental animal study. 2008

Mahmoud Reda, and Maha Zickri

Theodor Bilharz Research Institute, P.O. Box 30, Imbaba, Giza, Egypt.

Twenty six male albino rats were divided into a control group (6rats) (G) exposed to Sham operation and two experimental groups (G1 & G2) of 10 rats each. 2/3 partial hepatectomy (PH) was performed in G1 and T4 was administered orally in a dose of 4 mg/kg 10 days prior to PH in G2. Animals were sacrificed 24 hours following PH and Sham operation. Liver sections were immunohistochemically stained for anti-cyclin D1 & anti-VEGF antibodies. Positive reaction was in the nuclei of hepatocytes and in lining of hepatic blood sinusoids respectively. The morphometric determination of the count of cyclin D1 positive nuclei and area % VEGF positive lining of the blood sinusoids was performed in the different groups. Multiple cyclin D1 positive nuclei were detected in liver sections of rats receiving thyroxine prior to PH confirmed by significant increase in the mean count of immuno-positive nuclei as compared to G & G1. VEGF positive immuno-reaction was in the lining of multiple hepatic blood sinusoids on thyroxine therapy proved morphometrically by a significant increase in mean area % in G2 versus G1. The results showed a stimulating effect of thyroxine on liver regeneration following 2/3 partial hepatectomy evidenced by increased Cyclin D and sinusoidal endothelial VEGF expression.

UI	MeSH Term	Description	Entries
D008099	Liver	A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances.	Livers
D008115	Liver Regeneration	Repair or renewal of hepatic tissue.	Liver Regenerations,Regeneration, Liver,Regenerations, Liver
D008297	Male		Males
D011897	Random Allocation	A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects.	Randomization,Allocation, Random
D004195	Disease Models, Animal	Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	Animal Disease Model,Animal Disease Models,Disease Model, Animal
D006498	Hepatectomy	Excision of all or part of the liver. (Dorland, 28th ed)	Hepatectomies
D000818	Animals	Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA.	Animal,Metazoa,Animalia
D013974	Thyroxine	The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.	L-Thyroxine,Levothyroxine,T4 Thyroid Hormone,3,5,3',5'-Tetraiodothyronine,Berlthyrox,Dexnon,Eferox,Eltroxin,Eltroxine,Euthyrox,Eutirox,L-3,5,3',5'-Tetraiodothyronine,L-Thyrox,L-Thyroxin Henning,L-Thyroxin beta,L-Thyroxine Roche,Levo-T,Levothroid,Levothyroid,Levothyroxin Deladande,Levothyroxin Delalande,Levothyroxine Sodium,Levoxine,Levoxyl,Lévothyrox,Novothyral,Novothyrox,O-(4-Hydroxy-3,5-diiodophenyl) 3,5-diiodo-L-tyrosine,O-(4-Hydroxy-3,5-diiodophenyl)-3,5-diiodotyrosine,Oroxine,Sodium Levothyroxine,Synthroid,Synthrox,Thevier,Thyrax,Thyroxin,Tiroidine,Tiroxina Leo,Unithroid,L Thyrox,L Thyroxin Henning,L Thyroxin beta,L Thyroxine,L Thyroxine Roche,Levo T,Thyroid Hormone, T4
D016213	Cyclins	A large family of regulatory proteins that function as accessory subunits to a variety of CYCLIN-DEPENDENT KINASES. They generally function as ENZYME ACTIVATORS that drive the CELL CYCLE through transitions between phases. A subset of cyclins may also function as transcriptional regulators.	Cyclin
D042461	Vascular Endothelial Growth Factor A	The original member of the family of endothelial cell growth factors referred to as VASCULAR ENDOTHELIAL GROWTH FACTORS. Vascular endothelial growth factor-A was originally isolated from tumor cells and referred to as "tumor angiogenesis factor" and "vascular permeability factor". Although expressed at high levels in certain tumor-derived cells it is produced by a wide variety of cell types. In addition to stimulating vascular growth and vascular permeability it may play a role in stimulating VASODILATION via NITRIC OXIDE-dependent pathways. Alternative splicing of the mRNA for vascular endothelial growth factor A results in several isoforms of the protein being produced.	Vascular Endothelial Growth Factor,Vascular Endothelial Growth Factor-A,GD-VEGF,Glioma-Derived Vascular Endothelial Cell Growth Factor,VEGF,VEGF-A,Vascular Permeability Factor,Vasculotropin,Glioma Derived Vascular Endothelial Cell Growth Factor,Permeability Factor, Vascular